Literature DB >> 11035660

Prognosis and recurrent patterns in bronchioloalveolar carcinoma.

Y Y Liu1, Y M Chen, M H Huang, R P Perng.   

Abstract

STUDY
OBJECTIVE: Bronchioloalveolar carcinoma (BAC) is an uncommon pulmonary neoplasm with various radiologic and clinical presentations. In this article, we analyze the initial radiologic findings, TNM stagings, surgical types, and radiologic features of recurrence, and correlate them with patient survival.
DESIGN: A retrospective review of 93 patients who underwent resection for BAC from February 1989 to May 1999. PATIENTS: There were a total of 153 patients with BAC diagnosed during this period. Among them, 60 patients (39.2%) had diffuse disease and received medical therapy only, and the remaining 93 patients (60.8%), who had localized disease, underwent surgical resection. Patients who received surgical resection were enrolled in this study. MEASUREMENTS: Data regarding demographics, presentation symptoms, initial radiologic features, surgical type, tumor staging, recurrence status, radiologic patterns of recurrence, and survival were obtained from all patients.
RESULTS: Female patients were significantly younger than male patients. Patients who were female, nonsmoking, undergoing curative surgery, lobectomy, or bilobectomy, and with early tumor staging and no nodal involvement had a better prognosis. Patients with a right lung tumor had a longer survival than those with a left lung tumor, with borderline significance. Among those who suffered from recurrent diseases, a second resection yielded a better survival. Multivariate analysis showed curative surgery, initial surgical type, recurrence status, radiologic patterns of recurrence, and duration from surgical resection to recurrence all had a significant impact on survival.
CONCLUSIONS: Those patients with localized, early-stage BAC who underwent curative surgery had a better survival. Patients with localized recurrence after the initial surgery warranted a second resection. Those with a diffuse radiologic pattern of recurrence and/or early recurrence had a worse prognosis.

Entities:  

Mesh:

Year:  2000        PMID: 11035660     DOI: 10.1378/chest.118.4.940

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Recurrent "pneumonia" in left lower lobe lasting for 8 years: a case report.

Authors:  Dong-Mei Yuan; Yan-Wen Yao; Qian Li; Chen-Yang Liu; Pei Li; E-Hong Cao; Xin-Wu Xiao; Xin Su; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

2.  Breast cancer anti-estrogen resistance protein 1 (BCAR1/p130cas) in pulmonary disease tissue and serum.

Authors:  Bo Deng; Wei Huang; Qun-You Tan; Xiao-Qing Fan; Yao-Guang Jiang; Ling Liu; Ya-Yi Zhong; Yong-Gang Liang; Ru-Wen Wang
Journal:  Mol Diagn Ther       Date:  2011-02-01       Impact factor: 4.074

3.  Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples.

Authors:  Yi-Ching Wang; Yung-Pin Lu; Ruo-Chia Tseng; Ruo-Kai Lin; Jer-Wei Chang; Jung-Ta Chen; Chuen-Ming Shih; Chih-Yi Chen
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  Clinical characteristics and prognosis of nonsurgically treated patients with pneumonic-type adenocarcinoma.

Authors:  Jia Wei; Dezhu Tang; Ying Nie; Jie Chen; Li Peng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

5.  Unusual presentation of primary lung adenocarcinoma mimicking pneumonia: Case report and literature review.

Authors:  Asil Daoud; Amir Laktineh; Said El Zein; Ayman O Soubani
Journal:  Respir Med Case Rep       Date:  2019-06-14

6.  Stereotactic body radiation therapy for the treatment of early-stage minimally invasive adenocarcinoma or adenocarcnioma in situ (formerly bronchioloalveolar carcinoma): a patterns of failure analysis.

Authors:  Shahed N Badiyan; Andrew J Bierhals; Jeffrey R Olsen; Kimberly M Creach; Adam A Garsa; Todd Dewees; Jeffrey D Bradley; Clifford G Robinson
Journal:  Radiat Oncol       Date:  2013-01-03       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.